Literature DB >> 17974952

Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis.

Lingeng Lu1, Dionyssios Katsaros, Irene A Rigault de la Longrais, Olga Sochirca, Herbert Yu.   

Abstract

MicroRNAs (miRNA) are endogenous noncoding small RNAs that regulate the activity of mRNAs. Many miRNA genes, including let-7a-3, are located in CpG islands, suggesting possible epigenetic regulation of their expression. Promoter CpG island methylation of tumor suppressor genes is involved in cancer development and progression. Using real-time methylation-specific PCR and real-time reverse transcription-PCR, we analyzed DNA methylation in the let-7a-3 gene and miRNA expression of let-7a in 214 patients with epithelial ovarian cancer to assess the effect of let-7a-3 methylation on the expressions of let-7a as well as a possible target of let-7 regulation, insulin-like growth factor-II (IGF-II). The association of let-7a-3 methylation with patient survival outcomes was also evaluated. let-7a-3 methylation was detected in epithelial ovarian cancer, and the expression of let-7a was slightly affected by the methylation, but the effect was not substantial. The methylation of let-7a-3, however, was inversely correlated with IGF-II expression and positively with insulin-like growth factor binding protein-3 (IGFBP-3) expression. Patients with methylated let-7a-3 seemed to have reduced risk for death compared with those without, and the association was independent of patient age at surgery, tumor grade, disease stage, and IGF-II or IGFBP-3 expression. No association was found for let-7a-3 methylation and disease progression. These results suggest that the let-7a-3 gene is methylated and the methylation may affect IGF-II expression and the survival of ovarian cancer patients. Further investigation of the role of miRNAs and their regulation in cancer is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17974952     DOI: 10.1158/0008-5472.CAN-07-2544

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  114 in total

1.  miRNAs in human cancer.

Authors:  Xiaomin Zhong; George Coukos; Lin Zhang
Journal:  Methods Mol Biol       Date:  2012

2.  The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.

Authors:  Aaron E Hoffman; Tongzhang Zheng; Chun-Hui Yi; Richard G Stevens; Yue Ba; Yawei Zhang; Derek Leaderer; Theodore Holford; Johnni Hansen; Yong Zhu
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-16

3.  A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Authors:  Elena Ratner; Lingeng Lu; Marta Boeke; Rachel Barnett; Sunitha Nallur; Lena J Chin; Cory Pelletier; Rachel Blitzblau; Renata Tassi; Trupti Paranjape; Pei Hui; Andrew K Godwin; Herbert Yu; Harvey Risch; Thomas Rutherford; Peter Schwartz; Alessandro Santin; Ellen Matloff; Daniel Zelterman; Frank J Slack; Joanne B Weidhaas
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 4.  miRNAs: effectors of environmental influences on gene expression and disease.

Authors:  Alice Hudder; Raymond F Novak
Journal:  Toxicol Sci       Date:  2008-02-16       Impact factor: 4.849

Review 5.  Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?

Authors:  Lingeng Lu; Yixing Wu; Lingjun Zuo; Xingguang Luo; Peter J Large
Journal:  World J Microbiol Biotechnol       Date:  2013-10-09       Impact factor: 3.312

6.  miR-182 as a prognostic marker for glioma progression and patient survival.

Authors:  Lili Jiang; Pu Mao; Libing Song; Jueheng Wu; Jieting Huang; Chuyong Lin; Jie Yuan; Lianghu Qu; Shi-Yuan Cheng; Jun Li
Journal:  Am J Pathol       Date:  2010-05-14       Impact factor: 4.307

7.  MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf¹/cip¹).

Authors:  Assaad Semaan; Aamer M Qazi; Shelly Seward; Sreedhar Chamala; Christopher S Bryant; Sanjeev Kumar; Robert Morris; Christopher P Steffes; David L Bouwman; Adnan R Munkarah; Donald W Weaver; Scott A Gruber; Ramesh B Batchu
Journal:  Pharm Res       Date:  2011-08-05       Impact factor: 4.200

8.  MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer.

Authors:  Nuo Yang; Sippy Kaur; Stefano Volinia; Joel Greshock; Heini Lassus; Kosei Hasegawa; Shun Liang; Arto Leminen; Shan Deng; Lori Smith; Cameron N Johnstone; Xian-Ming Chen; Chang-Gong Liu; Qihong Huang; Dionyssios Katsaros; George Adrian Calin; Barbara L Weber; Ralf Bützow; Carlo M Croce; George Coukos; Lin Zhang
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.

Authors:  Lin Zhang; Stefano Volinia; Tomas Bonome; George Adrian Calin; Joel Greshock; Nuo Yang; Chang-Gong Liu; Antonis Giannakakis; Pangiotis Alexiou; Kosei Hasegawa; Cameron N Johnstone; Molly S Megraw; Sarah Adams; Heini Lassus; Jia Huang; Sippy Kaur; Shun Liang; Praveen Sethupathy; Arto Leminen; Victor A Simossis; Raphael Sandaltzopoulos; Yoshio Naomoto; Dionyssios Katsaros; Phyllis A Gimotty; Angela DeMichele; Qihong Huang; Ralf Bützow; Anil K Rustgi; Barbara L Weber; Michael J Birrer; Artemis G Hatzigeorgiou; Carlo M Croce; George Coukos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

Review 10.  MicroRNAs in ovarian carcinomas.

Authors:  Neetu Dahiya; Patrice J Morin
Journal:  Endocr Relat Cancer       Date:  2010-01-29       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.